home / stock / acet / acet articles
No one has written and article on Aceto Corporation, stock symbol ACET. Be the first to contribute and write an article.
News, Short Squeeze, Breakout and More Instantly...
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL) , a s of May 31, 2022 data-cut date 80% ORR and CR rate at dose...
As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a favorable safety and tolerability profile Updated data from a May 31, 2022 data-cut date will be presented during oral presentat...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor confere...